RH Genotype Matched RBC Transfusions

Launched by CHILDREN'S HOSPITAL OF PHILADELPHIA · Nov 6, 2019

Keywords

ClinConnect Summary

This clinical trial, called "RH Genotype Matched RBC Transfusions," is exploring a new approach to blood transfusions for patients with Sickle Cell Disease (SCD). The goal is to see if matching the donor red blood cells to the patient's RH genotype (a specific genetic marker) can improve the effectiveness of transfusions for those who need them regularly. This study is currently looking for participants, and anyone aged six months or older with a diagnosis of SCD may be eligible, as long as they require ongoing blood transfusions and have permission from a parent or guardian.

If you or your child join this trial, you can expect to receive blood transfusions that are specifically matched to your RH genotype, which may help reduce potential complications and improve treatment outcomes. However, certain factors, like having a rare RH genotype or specific immune responses to blood, may affect eligibility. This study is an important step in finding better ways to manage Sickle Cell Disease and improve the lives of those who live with it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects age \>6 months
• • Diagnosis of SCD, all genotypes
• • Require a period of chronic red cell transfusion therapy
• • Subject/parental/guardian permission (informed consent) and if appropriate, child assent
• Exclusion Criteria:
• • Rare RH genotype that would preclude identification of sufficient RBC units
• • Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units
• • Alloimmunized to D antigen
• • Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols
• • Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures